Literature DB >> 18213632

The metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions.

Natalie J Serkova1, Eduard J Gamito, Richard H Jones, Colin O'Donnell, Jaimi L Brown, Spencer Green, Holly Sullivan, Tammy Hedlund, E David Crawford.   

Abstract

OBJECTIVES: Due to specific physiological functions, prostatic tissues and fluids have unique metabolic profiles. In this study, proton nuclear magnetic resonance spectroscopy ((1)H-NMRS) is used to assess potential metabolic markers of prostate cancer (PCa) in human expressed prostatic secretions (EPS).
METHODS: Metabolic profiles of EPS from 52 men with PCa and from 26 healthy controls were analyzed using quantitative (1)H-NMRS. The metabolites quantified included citrate, spermine, myo-inositol, lactate, alanine, phosphocholine, glutamine, acetate, and hydroxybutyrate. Logistic regression (LR) was used to model the risk of PCa based on metabolite concentrations while adjusting for age.
RESULTS: The average age of the EPS donors with PCa was 58.0+/-7.0 years and 52.2+/-12.1 for the healthy donors. The median Gleason score for the men with PCa was 7 (range 5-9). The LR models indicated that the absolute concentrations of citrate, myo-inositol, and spermine were highly predictive of PCa and inversely related to the risk of PCa. The areas under the receiver operating characteristic curves (AUROC) for citrate, myo-inositol and spermine were 0.89, 0.87, and 0.79, respectively. At 90% sensitivity, these metabolites had specificities of 74%, 51%, and 34%, respectively. The LR analysis indicated that absolute levels of these three metabolites were independent of age.
CONCLUSIONS: The results indicate that citrate, myo-inositol and spermine are potentially important markers of PCa in human EPS. Further, the absolute concentrations of these metabolites in EPS appear to be independent of age, increasing the potential utility of these markers due to elimination of age as a confounding variable.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18213632     DOI: 10.1002/pros.20727

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  49 in total

Review 1.  Application of metabolomics to prostate cancer.

Authors:  Bruce J Trock
Journal:  Urol Oncol       Date:  2011 Sep-Oct       Impact factor: 3.498

2.  Delineating metabolic signatures of head and neck squamous cell carcinoma: phospholipase A2, a potential therapeutic target.

Authors:  Pratima Tripathi; Pachiyappan Kamarajan; Bagganahalli S Somashekar; Neil MacKinnon; Arul M Chinnaiyan; Yvonne L Kapila; Thekkelnaycke M Rajendiran; Ayyalusamy Ramamoorthy
Journal:  Int J Biochem Cell Biol       Date:  2012-06-26       Impact factor: 5.085

3.  Assessing prostate cancer growth with citrate measured by intact tissue proton magnetic resonance spectroscopy.

Authors:  R Dittrich; J Kurth; E A Decelle; E M DeFeo; M Taupitz; S Wu; C-L Wu; W S McDougal; L L Cheng
Journal:  Prostate Cancer Prostatic Dis       Date:  2012-01-31       Impact factor: 5.554

4.  Selective apoptosis induction by the cancer chemopreventive agent N-(4-hydroxyphenyl)retinamide is achieved by modulating mitochondrial bioenergetics in premalignant and malignant human prostate epithelial cells.

Authors:  Numsen Hail; Ping Chen; Jadwiga J Kepa
Journal:  Apoptosis       Date:  2009-07       Impact factor: 4.677

5.  Recent Advances in Metabolic Profiling And Imaging of Prostate Cancer.

Authors:  Roopa Thapar; Mark A Titus
Journal:  Curr Metabolomics       Date:  2014-04

Review 6.  Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence.

Authors:  Rachel S Kelly; Matthew G Vander Heiden; Edward Giovannucci; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-04-06       Impact factor: 4.254

Review 7.  Metabolomics-based methods for early disease diagnostics.

Authors:  G A Nagana Gowda; Shucha Zhang; Haiwei Gu; Vincent Asiago; Narasimhamurthy Shanaiah; Daniel Raftery
Journal:  Expert Rev Mol Diagn       Date:  2008-09       Impact factor: 5.225

8.  Inositol hexaphosphate inhibits tumor growth, vascularity, and metabolism in TRAMP mice: a multiparametric magnetic resonance study.

Authors:  Komal Raina; Kameswaran Ravichandran; Subapriya Rajamanickam; Kendra M Huber; Natalie J Serkova; Rajesh Agarwal
Journal:  Cancer Prev Res (Phila)       Date:  2012-12-04

Review 9.  Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease.

Authors:  Richard R Drake; Krista Y White; Thomas W Fuller; Elena Igwe; Mary Ann Clements; Julius O Nyalwidhe; Robert W Given; Raymond S Lance; O John Semmes
Journal:  J Proteomics       Date:  2009-01-20       Impact factor: 4.044

10.  A novel scoring system for prognostic prediction in d-galactosamine/lipopolysaccharide-induced fulminant hepatic failure BALB/c mice.

Authors:  Bo Feng; Sheng Ming Wu; Sa Lv; Feng Liu; Hong Song Chen; Yan Gao; Fang Ting Dong; Lai Wei
Journal:  BMC Gastroenterol       Date:  2009-12-30       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.